---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-035212"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:39:02.644716+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics promotes Khurram Jamil to CMO, replacing Pol Boudes

## Summary
- Dr. Jamil appointed Chief Medical Officer effective August 1, 2024, succeeding Dr. Pol Boudes.
- Annual base salary of $500,000, 30% target bonus, 10,000 restricted shares, options for 100,000 shares.
- Jamil joined Galectin in March 2024 as VP Clinical Development; previously at Mallinckrodt Pharmaceuticals.
- Company reaffirms interim analysis of NAVIGATE Phase 2b/3 trial for belapectin in December 2024.

## SEC filing metadata
- accession: 0001140361-24-035212
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/ef20033332_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-035212
- JSON: https://secwatch.observer/filing/0001140361-24-035212.json
- Plain text: https://secwatch.observer/filing/0001140361-24-035212.txt

## Key facts
- Executive change
  Pol Boudes resigned as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
  - Action: resigned
  - Role: Chief Medical Officer
  source text: Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm
- Executive change
  Khurram Jamil changed role as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
  - Action: promoted
  - Role: Chief Medical Officer
  source text: On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036124035212/0001140361-24-035212-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.